Want to see GRDN full AI Analyst Report?
GRDN Stock Chart & Stats
$37.54
$0.47(2.39%)
At close: 4:00 PM EST
$37.54
$0.47(2.39%)
Day’s Range― - ―
52-Week Range$19.30 - $44.00
Previous Close$20.98
Volume93.63K
Average Volume (3M)348.83K
Market Cap
$2.66B
Enterprise Value$2.72B
Total Cash (Recent Filing)$64.89M
Total Debt (Recent Filing)$36.88M
Price to Earnings (P/E)49.4
Beta0.52
Next Earnings
Aug 17, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding49,781,180
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit8.93
Enterprise Value/Ebitda26.59
Forecast
1Y Price Target
$47.50Price Target Upside26.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.26
Revenue Forecast (FY)$1.41B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthVery low leverage and materially expanded equity create durable financial flexibility. A strong capital structure reduces refinancing risk, supports opportunistic M&A and greenfield investment, and cushions short-term cashflow variability, improving resilience over coming quarters.
Accelerating Revenue MomentumRapid top-line acceleration and higher resident/script volumes indicate persistent organic growth and scale gains. Sustained revenue expansion strengthens payor negotiating leverage and spreads fixed costs, helping support margin recovery and longer-term profitability.
Greater Liquidity And Covenant FlexibilityExtended credit facility maturity, higher potential borrowing capacity, and recalibrated covenants increase runway for operations and M&A. This structural financing flexibility reduces near-term liquidity risk and enables strategic deployment of capital over the next 2–6 months.
Bears Say
IRA-driven Branded Pricing CutsA severe, regulatory-driven decline in branded pricing is structural and reduces revenue per unit for affected products. Persistent policy impacts will pressure gross margins and require sustained payor renegotiation and operational mitigation to preserve profitability over the medium term.
Thin, Volatile MarginsRelatively low absolute margins and historical earnings volatility mean small cost or price moves materially affect profits and free cash flow. Margin sensitivity limits ability to absorb headwinds like fuel, labor, or pricing shocks without eroding cash generation or requiring corrective actions.
Acquisition Integration DragBelow-cohort acquisition margins and integration costs are a recurring drag on consolidated profitability. Continued dilution from new operators through 2026–2027 raises execution risk, slowing margin expansion and reducing the durability of reported earnings improvements.
Guardian Pharmacy Services, Inc. Class A News
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
Guardian Pharmacy Services, Inc. Class A lowest stock price was $19.30 and its highest was $44.00 in the past 12 months.
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
Guardian Pharmacy Services, Inc. Class A’s market cap is $2.66B.
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Guardian Pharmacy Services, Inc. Class A released its earnings results on May 06, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.05.
Is Guardian Pharmacy Services, Inc. Class A overvalued?
According to Wall Street analysts Guardian Pharmacy Services, Inc. Class A’s price is currently Undervalued.
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
Guardian Pharmacy Services, Inc. Class A does not currently pay dividends.
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
Guardian Pharmacy Services, Inc. Class A’s EPS estimate is 0.26.
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
Guardian Pharmacy Services, Inc. Class A has 49,781,180 shares outstanding.
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Guardian Pharmacy Services, Inc. Class A reported an EPS of $0.29 in its last earnings report, beating expectations of $0.24. Following the earnings report the stock price went down -0.847%.
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
Currently, no hedge funds are holding shares in GRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.50 (26.53% Upside)
$47.50 (26.53% Upside)
Hedge Fund Trend
Increased
By 249.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.50%
12-Months-Change
Fundamentals
Return on Equity
27.21%
Trailing 12-Months
Asset Growth
27.83%
Trailing 12-Months
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
GRDN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a positive operational and financial outturn for Q1 2026: the company successfully navigated major IRA-driven disruption, delivered revenue resilience, strong gross profit and adjusted EBITDA growth, and raised adjusted EBITDA guidance. Key risks remain, including a severe (~60%) branded pricing decline caused by the IRA, temporary working capital and payment-timing stresses, margin pressure from recent acquisitions (~80 bps drag), and potential cost headwinds from fuel and labor. Management emphasized scale advantages, proactive payor negotiations, and confidence in normalization of working capital, while noting that certain quarter-specific benefits are non-recurring. On balance, highlights demonstrating execution and financial strength outweigh the lowlights tied mainly to one-time disruptions and ongoing cost/legislative uncertainty.View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
$47.50
▲(26.53% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---